Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 179

1.

MicroRNAs and inflammation in the pathogenesis and progression of colon cancer.

Okayama H, Schetter AJ, Harris CC.

Dig Dis. 2012;30 Suppl 2:9-15. doi: 10.1159/000341882. Epub 2012 Nov 23. Review.

PMID:
23207927
2.

The pathological role of microRNAs and inflammation in colon carcinogenesis.

Zhang L, Fan XM.

Clin Res Hepatol Gastroenterol. 2015 Apr;39(2):174-9. doi: 10.1016/j.clinre.2014.06.013. Epub 2014 Aug 19. Review.

PMID:
25154001
3.

Colon carcinogenesis in inflammatory bowel disease: applying molecular genetics to clinical practice.

Itzkowitz S.

J Clin Gastroenterol. 2003 May-Jun;36(5 Suppl):S70-4; discussion S94-6. Review.

PMID:
12702969
4.

Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer.

Arndt GM, Dossey L, Cullen LM, Lai A, Druker R, Eisbacher M, Zhang C, Tran N, Fan H, Retzlaff K, Bittner A, Raponi M.

BMC Cancer. 2009 Oct 20;9:374. doi: 10.1186/1471-2407-9-374.

5.

Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis.

Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, Nykter M, Harris CC, Chen K, Hamilton SR, Zhang W.

PLoS One. 2011 Mar 17;6(3):e17745. doi: 10.1371/journal.pone.0017745.

6.

MicroRNA in colorectal cancer: from benchtop to bedside.

Wu WK, Law PT, Lee CW, Cho CH, Fan D, Wu K, Yu J, Sung JJ.

Carcinogenesis. 2011 Mar;32(3):247-53. doi: 10.1093/carcin/bgq243. Epub 2010 Nov 16. Review.

PMID:
21081475
7.

Diagnostic and prognostic microRNAs in stage II colon cancer.

Schepeler T, Reinert JT, Ostenfeld MS, Christensen LL, Silahtaroglu AN, Dyrskjøt L, Wiuf C, Sørensen FJ, Kruhøffer M, Laurberg S, Kauppinen S, Ørntoft TF, Andersen CL.

Cancer Res. 2008 Aug 1;68(15):6416-24. doi: 10.1158/0008-5472.CAN-07-6110.

8.

microRNAs as oncogenes and tumor suppressors.

Zhang B, Pan X, Cobb GP, Anderson TA.

Dev Biol. 2007 Feb 1;302(1):1-12. Epub 2006 Aug 16. Review.

9.

Colon cancer in inflammatory bowel disease: recent trends, questions and answers.

Viennot S, Deleporte A, Moussata D, Nancey S, Flourié B, Reimund JM.

Gastroenterol Clin Biol. 2009 Jun;33 Suppl 3:S190-201. doi: 10.1016/S0399-8320(09)73154-9.

10.

Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis.

Wang LG, Gu J.

Cancer Epidemiol. 2012 Feb;36(1):e61-7. doi: 10.1016/j.canep.2011.05.002. Epub 2011 Oct 21.

PMID:
22018950
11.

MicroRNAs in colorectal cancer: small molecules with big functions.

Xuan Y, Yang H, Zhao L, Lau WB, Lau B, Ren N, Hu Y, Yi T, Zhao X, Zhou S, Wei Y.

Cancer Lett. 2015 May 1;360(2):89-105. doi: 10.1016/j.canlet.2014.11.051. Epub 2014 Dec 15. Review.

PMID:
25524553
12.

Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review).

Allegra A, Alonci A, Campo S, Penna G, Petrungaro A, Gerace D, Musolino C.

Int J Oncol. 2012 Dec;41(6):1897-912. doi: 10.3892/ijo.2012.1647. Epub 2012 Oct 1. Review.

PMID:
23026890
13.

Small RNAs have a large impact: circulating microRNAs as biomarkers for human diseases.

Weiland M, Gao XH, Zhou L, Mi QS.

RNA Biol. 2012 Jun;9(6):850-9. doi: 10.4161/rna.20378. Epub 2012 Jun 1. Review.

PMID:
22699556
14.

The role of variations within microRNA in inflammatory bowel disease.

Papaconstantinou I, Stamatis K, Tzathas C, Vassiliou I, Giokas G, Gazouli M.

Eur J Gastroenterol Hepatol. 2013 Apr;25(4):399-403. doi: 10.1097/MEG.0b013e32835c34ea. Review.

PMID:
23466513
15.

MicroRNAs as oncogenes or tumour suppressors in oesophageal cancer: potential biomarkers and therapeutic targets.

Huang J, Zhang SY, Gao YM, Liu YF, Liu YB, Zhao ZG, Yang K.

Cell Prolif. 2014 Aug;47(4):277-86. doi: 10.1111/cpr.12109. Epub 2014 Jun 6. Review.

PMID:
24909356
16.

MicroRNA signatures: novel biomarker for colorectal cancer?

Luo X, Burwinkel B, Tao S, Brenner H.

Cancer Epidemiol Biomarkers Prev. 2011 Jul;20(7):1272-86. doi: 10.1158/1055-9965.EPI-11-0035. Epub 2011 May 6. Review.

17.

The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies.

Corsini LR, Bronte G, Terrasi M, Amodeo V, Fanale D, Fiorentino E, Cicero G, Bazan V, Russo A.

Expert Opin Ther Targets. 2012 Apr;16 Suppl 2:S103-9. doi: 10.1517/14728222.2011.650632. Epub 2012 Mar 23. Review.

PMID:
22443195
18.

[Recent progress on miRNAs in the pathogenesis of colon cancer].

Tang JT, Fang JY.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2008 Jun;25(3):297-9. Review. Chinese.

PMID:
18543220
19.

The lymphatic system controls intestinal inflammation and inflammation-associated Colon Cancer through the chemokine decoy receptor D6.

Vetrano S, Borroni EM, Sarukhan A, Savino B, Bonecchi R, Correale C, Arena V, Fantini M, Roncalli M, Malesci A, Mantovani A, Locati M, Danese S.

Gut. 2010 Feb;59(2):197-206. doi: 10.1136/gut.2009.183772. Epub 2009 Oct 20.

PMID:
19846409
20.

MicroRNA dysregulation in gastric cancer.

Pan HW, Li SC, Tsai KW.

Curr Pharm Des. 2013;19(7):1273-84. Review.

PMID:
23092346

Supplemental Content

Support Center